At a glance
ClinicalIndex Comparison RecordN/ACompleted· 35 enrolled
Drug / intervention
florbetapir F 18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Physician Training for Interpretation of Florbetapir-PET Scans: Validation of Binary Image Rating Methodology Using Amyloid Histopathology at Autopsy as the Reference Standard.
In Brief
A clinical study evaluating florbetapir F 18 for Alzheimer's Disease. Completed, enrolled 35 participants.
Detailed Summary
The purpose of this study is re-read of brain amyloid positron emission tomography (PET) scans acquired in previous florbetapir F 18 clinical studies by readers trained using updated reading methodology. The scans in this study came from subjects who had an autopsy to reveal the subject's true amyloid status.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
Primary CompletionJan 2011
First PostedMar 2012
TodayJul 2026
First PostedMar 28, 2012
Enrollment StartJan 1, 2011
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 14.3 years ago
Interventions
florbetapir F 18drug
IV injection, 370MBq (10mCi), single dose